Biocon integrates biosimilars business of Viatris in 31 countries

[ad_1] Biocon Biologics has completed the integration of Viatris’ biosimilars business across countries in Europe. Credit: Biocon. Biocon subsidiary Biocon Biologics has successfully integrated Viatris‘ biosimilars business in 31 countries…

Biocon’s subsidiary completes integration of Viatris’ biosimilars business; stock rises

[ad_1] Biocon share price: Biocon shares on Friday, December 1, rose over 2 per cent to touch the intra-day high of Rs 245 apiece on BSE, rising for the third…

Biosimilar Business Roundup for October 2023—Podcast Edition

[ad_1] Biosimilar Business Roundup for October 2023—Podcast Edition  The Center for Biosimilars [ad_2] Source link

Biologics and Biosimilars Market Size in 2023 | long-term Calculated Business Plan and DRIVING FORCES till 2030

[ad_1] PRESS RELEASE Published September 22, 2023

Meitheal partners with Chinese company for US licencing of insulin biosimilars – Pharmaceutical Technology

[ad_1] The availability of biosimilars can help reduce the cost of insulin therapies. Image Credit: Daniel Beckemeier / Shutterstock. Meitheal Pharmaceuticals has signed an exclusive licensing agreement with the China-based…

Biocon may list biosimilars business by 2025 first half – CEO

[ad_1] An employee of Biocon Ltd works inside the company’s research and development centre in Bengaluru, India, October 16, 2015. REUTERS/Abhishek N. Chinnappa/File Photo HYDERABAD, Aug 11 (Reuters) – Indian…

The global biosimilars market size is projected to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8%

[ad_1] New York, June 26, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Biosimilars Market by Drug, Indication, Region – Global Forecast to 2028” – https://www.reportlinker.com/p04604343/?utm_source=GNW during…

France Biosimilars Business and Investment Opportunities to 2027

[ad_1] Company Logo Dublin, May 08, 2023 (GLOBE NEWSWIRE) — The “France Biosimilars Business and Investment Opportunities Databook – Q1 2023 Update” report has been added to ResearchAndMarkets.com’s offering. France’s…

Japan Biosimilars Business and Investment Opportunities Report 2023: Market Size is Expected to Record a CAGR of 29.2% During 2023-2027 to Reach US$3,203.6 Million by 2027

[ad_1] Dublin, May 05, 2023 (GLOBE NEWSWIRE) — The “Japan Biosimilars Business and Investment Opportunities Databook – Q1 2023 Update” report has been added to ResearchAndMarkets.com’s offering. Japan’s biosimilar market…

Canada Biosimilars Business and Investment Opportunities Databook, 2018-2022 & 2023-2027

[ad_1] Dublin, May 05, 2023 (GLOBE NEWSWIRE) — The “Canada Biosimilars Business and Investment Opportunities Databook – Q1 2023 Update” report has been added to ResearchAndMarkets.com’s offering. Canada’s biosimilar market…